Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Observational, Multicenter Clinical Performance Study to Evaluate IOpener®-Melanoma Test for Predicting Response to Combination or Mono Immunotherapy in Stage III or IV Cutaneous Melanoma Patients.

NCT06784778 is registered in ClinicalTrials.gov with Pamgene International B.V. as lead sponsor.

NCT NCT06784778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06784778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Observational, Multicenter Clinical Performance Study to Evaluate IOpener®-Melanoma Test for Predicting Response to Combination or Mono Immunotherapy in Stage III or IV Cutaneous Melanoma Patients.
Lead sponsor
Pamgene International B.V.
Phase
Observational
Overall status
Recruiting
Start date
July 12, 2024
Completion date
July 31, 2027
Enrollment
196 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma advanced, melanoma metastatic, melanoma stage iii or iv, melanoma, skin